158 related articles for article (PubMed ID: 16208151)
1. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
Jandeleit-Dahm K; Lassila M; Davis BJ; Candido R; Johnston CI; Allen TJ; Burrell LM; Cooper ME
J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
[TBL] [Abstract][Full Text] [Related]
2. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
Arnal JF; Castano C; Maupas E; Mugniot A; Darblade B; Gourdy P; Michel JB; Bayard F
Atherosclerosis; 2001 Apr; 155(2):291-5. PubMed ID: 11254898
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
Raasch W; Dominiak P; Dendorfer A
J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
Burrell LM; Droogh J; Man in't Veld O; Rockell MD; Farina NK; Johnston CI
Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
Bäcklund T; Palojoki E; Grönholm T; Eriksson A; Vuolteenaho O; Laine M; Tikkanen I
Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
[TBL] [Abstract][Full Text] [Related]
6. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
Pu Q; Touyz RM; Schiffrin EL
J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
[TBL] [Abstract][Full Text] [Related]
8. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
[TBL] [Abstract][Full Text] [Related]
9. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
Kubota E; Dean RG; Hubner RA; Casley DJ; Johnston CI; Burrell LM
Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
[TBL] [Abstract][Full Text] [Related]
10. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.
Watson AM; Li J; Schumacher C; de Gasparo M; Feng B; Thomas MC; Allen TJ; Cooper ME; Jandeleit-Dahm KA
Diabetologia; 2010 Jan; 53(1):192-203. PubMed ID: 19862499
[TBL] [Abstract][Full Text] [Related]
11. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
Mifsud SA; Burrell LM; Kubota E; Jaworski K; Cooper ME; Wilkinson-Berka JL
Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
[TBL] [Abstract][Full Text] [Related]
12. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
Cao Z; Burrell LM; Tikkanen I; Bonnet F; Cooper ME; Gilbert RE
Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
[TBL] [Abstract][Full Text] [Related]
14. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats.
Elmarakby AA; Morsing P; Pollock JS; Pollock DM
Vascul Pharmacol; 2003 Dec; 40(5):253-9. PubMed ID: 15259792
[TBL] [Abstract][Full Text] [Related]
15. Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.
Levy Z; Dvir A; Shaish A; Trestman S; Cohen H; Levkovietz H; Rhachmani R; Ravid M; Harats D
Int J Exp Diabesity Res; 2003; 4(1):59-64. PubMed ID: 12745671
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
[TBL] [Abstract][Full Text] [Related]
17. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice.
Watson AM; Soro-Paavonen A; Sheehy K; Li J; Calkin AC; Koitka A; Rajan SN; Brasacchio D; Allen TJ; Cooper ME; Thomas MC; Jandeleit-Dahm KJ
Diabetologia; 2011 Mar; 54(3):681-9. PubMed ID: 21161164
[TBL] [Abstract][Full Text] [Related]
18. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
[TBL] [Abstract][Full Text] [Related]
19. Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats.
Cheng ZJ; Grönholm T; Louhelainen M; Finckenberg P; Merasto S; Tikkanen I; Mervaala E
J Hypertens; 2005 Sep; 23(9):1757-70. PubMed ID: 16093923
[TBL] [Abstract][Full Text] [Related]
20. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]